Fate Therapeutics downgraded by BofA Securities with a new price target

1/6/23 8:17:16 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

BofA Securities downgraded Fate Therapeutics from Buy to Underperform and set a new price target of $4.00 from $72.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FATE

Date	Price Target	Rating	Analyst
11/18/2024		Underperform → Neutral	BofA Securities
6/17/2024	$4.00 → $6.00	Neutral → Overweight	Piper Sandler
3/27/2023	$6.00	Equal Weight	Wells Fargo
1/24/2023	$115.00 → $7.00	Buy → Neutral	H.C. Wainwright
1/6/2023	$20.00 → $7.00	Outperform → Market Perform	BMO Capital Markets
1/6/2023	$71.00 → $12.00	Overweight → Neutral	Piper Sandler
1/6/2023		Outperform → Market Perform	Cowen
1/6/2023	$107.00 → $5.30	Buy → Hold	Stifel